ELTD1 siRNA and anti‐ELTD1 antibodies reduced vessel density in ovarian and glioma tumour models thereby confirming its potential as an anti‐angiogenic therapeutic target (Masiero et al., 2013; Zalles et al., 2020). Here, ADGRL4 is linked to neoplasm.